OncoMatch/Clinical Trials/NCT05595447
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Is NCT05595447 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Brentuximab Vedotin 50 MG [Adcetris] for hodgkin lymphoma.
Treatment: Brentuximab Vedotin 50 MG [Adcetris] — The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Must have received: cytotoxic chemotherapy (ABVD)
Relapsed/refractory Hodgkin lymphoma to ABVD
Lab requirements
Kidney function
serum creatinine ≤ 1.5x uln or glomerular filtration rate > 50ml/min
Liver function
total serum bilirubin ≤ 1.5 x uln; ast ≤ 3.0 x uln; alt ≤ 3.0 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05595447 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cytotoxic chemotherapy.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 15 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages